行情

RARE

RARE

Ultragenyx药业
NASDAQ

实时行情|Nasdaq Last Sale

42.81
+1.15
+2.76%
交易中 15:07 10/15 EDT
开盘
41.65
昨收
41.66
最高
43.20
最低
41.65
成交量
37.59万
成交额
--
52周最高
74.50
52周最低
37.44
市值
24.70亿
市盈率(TTM)
-6.1087
分时
5日
1月
3月
1年
5年

分析师评级

19位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RARE 新闻

  • 邓普顿基金明星经理失手 旗舰债基三个月亏30亿美元
  • 新浪美股.49分钟前
  • 一文看懂谷歌秋季发布会:AI串联全家桶
  • 新浪科技.1小时前
  • 高盛表示已将持有的WeWork股权减记了8000万美元
  • 新浪美股.1小时前
  • 德国警告英国脱欧将推迟 协议不足以解决技术性问题
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
+2.02%
制药与医学研究
+1.32%

热门股票

名称
价格
涨跌幅

RARE 简况

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
展开

Webull提供Ultragenyx Pharmaceutical Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。